A detailed history of Marshall Wace, LLP transactions in Glaukos Corp stock. As of the latest transaction made, Marshall Wace, LLP holds 128,803 shares of GKOS stock, worth $18.6 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
128,803
Holding current value
$18.6 Million
% of portfolio
0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$113.62 - $135.39 $14.6 Million - $17.4 Million
128,803 New
128,803 $16.8 Million
Q1 2024

May 15, 2024

SELL
$76.4 - $96.33 $5.34 Million - $6.74 Million
-69,928 Reduced 95.62%
3,200 $301,000
Q4 2023

Feb 14, 2024

BUY
$59.53 - $85.11 $4.35 Million - $6.22 Million
73,128 New
73,128 $5.81 Million
Q1 2023

May 15, 2023

BUY
$43.88 - $52.48 $291,231 - $348,309
6,637 New
6,637 $332,000
Q3 2022

Nov 14, 2022

SELL
$46.84 - $58.49 $147,264 - $183,892
-3,144 Reduced 39.58%
4,800 $256,000
Q2 2022

Aug 15, 2022

SELL
$34.86 - $63.77 $63,445 - $116,061
-1,820 Reduced 18.64%
7,944 $361,000
Q1 2022

May 16, 2022

SELL
$44.33 - $57.82 $18.4 Million - $24 Million
-415,771 Reduced 97.71%
9,764 $565,000
Q4 2021

Feb 14, 2022

SELL
$40.27 - $56.99 $9.96 Million - $14.1 Million
-247,228 Reduced 36.75%
425,535 $18.9 Million
Q3 2021

Nov 15, 2021

BUY
$47.43 - $84.23 $31.7 Million - $56.3 Million
668,934 Added 17470.2%
672,763 $32.4 Million
Q2 2021

Aug 13, 2021

SELL
$73.06 - $97.7 $327,893 - $438,477
-4,488 Reduced 53.96%
3,829 $325,000
Q1 2021

May 17, 2021

SELL
$70.43 - $97.42 $348,628 - $482,229
-4,950 Reduced 37.31%
8,317 $698,000
Q4 2020

Feb 16, 2021

BUY
$48.9 - $75.26 $648,756 - $998,474
13,267 New
13,267 $999,000

Others Institutions Holding GKOS

About GLAUKOS Corp


  • Ticker GKOS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 47,596,900
  • Market Cap $6.86B
  • Description
  • Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...
More about GKOS
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.